Canada markets closed

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5800-0.0400 (-2.47%)
At close: 04:00PM EDT
1.5800 0.00 (0.00%)
After hours: 04:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.6200
Open1.6200
Bid1.5600 x 200
Ask1.6400 x 200
Day's Range1.5800 - 1.6471
52 Week Range0.6220 - 2.5000
Volume82,818
Avg. Volume622,066
Market Cap25.954M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-2.9600
Earnings DateMay 10, 2024 - May 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • Insider Monkey

    Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript

    Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]

  • Thomson Reuters StreetEvents

    Q4 2023 Iterum Therapeutics PLC Earnings Call

    Q4 2023 Iterum Therapeutics PLC Earnings Call

  • GlobeNewswire

    Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    --Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r